A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.
Artikel i vetenskaplig tidskrift, 2010

Multiple Outcomes of Raloxifene Evaluation (MORE), a placebo controlled phase III study of raloxifene in postmenopausal osteoporosis, showed that both doses tested (60 mg and 120 mg daily) reduced the risk of vertebral fracture. There was no significant effect on non-vertebral fracture.

epidemiology

Spinal Fractures

Placebos

Humans

Incidence

Proportional Hazards Models

therapeutic use

Algorithms

therapeutic use

epidemiology

Osteoporotic Fractures

80 and over

drug therapy

Risk Factors

Middle Aged

Treatment Outcome

Female

Adult

Aged

drug therapy

Raloxifene

Aged

Bone Density Conservation Agents

Författare

John A Kanis

Helena Johansson

Eugene V McCloskey

Bone

1873-2763 (ISSN)

Vol. 47 729-35

Ämneskategorier

Endokrinologi och diabetes

DOI

10.1016/j.bone.2010.06.009

PubMed

20601292